ORIXHA Overview
Established in 2018, ORIXHA is a DeepTech spin-off operating out of Maisons-Alfort, France. The company is known for its proprietary Total Liquid Ventilation (TLV) technology, a groundbreaking approach in respiratory support primarily aimed at improving outcomes for critical care and comatose patients. This technology involves the use of breathable liquids to ventilate the lungs, providing a new therapeutic horizon for conditions like Post Cardiac Arrest Syndrome and acute Respiratory Distress.
Mission and Innovation
ORIXHA's mission is "to save the lives of critical care patients through our unique liquid ventilation technology." The company’s LuncoLive platform, dubbed as "lung-protective by design," comprises the technological backbone for products like Vent2Cool and Vent2Breathe, which are yet to receive clinical validation. These devices aim to meet unmet medical needs by offering life-saving options for specific respiratory conditions. The Vent2Cool device and LuncoLive platform aim to save critical care patients post-cardiac arrest by protecting vital organs such as the brain and heart through liquid ventilation technology. This approach functions by using the lungs as a heat exchanger with the blood compartment, thereby reducing mortality and morbidity.
Funding and Financial Overview
ORIXHA has raised a total of €4 million from notable backers such as the European Innovation Council and Bpifrance. Their funding endeavors reflect a steady growth in capital, helping propel forward their research and development initiatives. Although specific revenue figures are not disclosed, recent valuations estimate the company’s enterprise value between €16 million and €24 million (source: Dealroom.co, April 2024). Their successful funding rounds underscore the trust and potential seen in ORIXHA's innovative technologies.
Recent Developments
- In April 2024, ORIXHA raised €4 million from the European Innovation Council Fund and Bpifrance, signaling strong investor confidence in their TLV technology.
- Achieved French Health Authority’s approval for a feasibility clinical study in Post Cardiac Arrest Syndrome as of September 2024.
Leadership Team
- Anne Reiser: Executive Chairwoman, leading the strategy and development for ORIXHA.
- Fabrice Paublant, MBA: Co-founder and CEO, focused on spearheading innovations for the Vent2Cool device, expected to introduce the first safe total liquid ventilation procedure along with ultra-rapid cooling capabilities.
- Renaud Tissier, DVM, PhD: Co-founder and Chief Medical Officer, recognized for his significant role in developing ORIXHA's technology and participating in high-profile medtech forums.
- Mathieu Nadeau, Eng. PhD: Co-founder and Chief Technology Officer, overseeing the technological advancements of the company.
- Sandrine Perrotto, PhD: Head of R&D for the V2C product, contributing to regulatory strategies and innovations in medical device technologies.
Technological Infrastructure
ORIXHA utilizes a suite of modern technological solutions to support its operations, including Microsoft Office 365 for productivity, Google Font API for visual branding, and WordPress.org as a content management system, ensuring a user-friendly, mobile-friendly, and professional online presence.
Contact Information
Address:
7 avenue du Général de Gaulle,
94700 Maisons-Alfort, France
Social Media:
- [LinkedIn](https://www.linkedin.com/company/orixha)
- [Twitter](https://twitter.com/orixha)
- [Vimeo](https://vimeo.com/orixha)
Competitive Landscape
ORIXHA operates in a competitive space with significant potential, given the emphasis on critical care innovations. While specific direct competitors are not listed, ORIXHA's unique focus on liquid ventilation positions it advantageously in a niche market within the broader medical device industry. The company's efforts to scale its pioneering liquid ventilation technology signify a promising trajectory in improving patient care in critical medical scenarios.
As ORIXHA continues to innovate and expand its product offerings, its strategic focus on enhancing intensive care outcomes presents valuable opportunities for partnerships and integration within broader health care delivery systems. ORIXHA represents a cutting-edge convergence of technology and healthcare, dedicated to transforming critical care through innovations that have the potential to significantly impact patient outcomes globally.
